Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 07/03/2024.
  • Additional Information
    • Alternate Title:
      INSMED-study-data-WBC
    • Subject Terms:
    • Abstract:
      —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo— [ABSTRACT FROM PUBLISHER]